Establishment of a Collection of Blood-Derived Products from COVID-19 Patients for Translational Research: Experience of the LPCE Biobank (Nice, France)

Tanga, Virginie; Leroy, Sylvie; Fayada, Julien; Hamila, Marame; Allègra, Maryline; Messaoudi, Zeineb; Bonnetaud, Christelle; Lespinet, Virginie; Bordone, Olivier; Washetine, Kevin; Griffonnet, Jennifer; Maniel, Charlotte; Philibert, Lorène; Selva, Éric; Benzaquen, Jonathan; Ilié, Marius; Long, Élodie; Lassalle, Sandra; Lanteri, Elisabeth; Marquette, Charles‐Hugo; Hofman, Véronique; Hofman, Paul

doi:10.1089/bio.2020.0055

Cited by 12 publications

(14 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, pathologists should be strengthened to assure the continuity of the COVID-19 biobanking. 33 Conversely, a number of the pathology laboratories included in the present work had the possibility to participate in and/or lead research projects into COVID-19. 33 , 34 , 35 , 36 , 37 Thus, at the time of submission of this study, 71 manuscripts were published or submitted for publication in association with one or several of these pathology laboratories, which was a fruitful consequence occurring in only a short period of time.…”

Section: Discussionmentioning

confidence: 99%

Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future

Hofman¹,

Ilié²,

Chamorey³

et al. 2021

ESMO Open

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future

Hofman¹,

Ilié²,

Chamorey³

et al. 2021

ESMO Open

View full text Add to dashboard Cite

“…OS were placed in the mouth by the subjects themselves, taken out after one minute and inserted into the collection tube (Figures 3S to 5S in the appendix). One NPS was transported within 4 hours in 3 ml medium (Remel MicroTest ™ M4RT ® ) along with the tubes containing the sponges in 2 ml of 0.9 % saline to the Idylla platform of the Laboratory of Clinical and Experimental Pathology (LPCE), (Pavilion I, Hôpital Pasteur 1, Nice) accredited by COFRAC according to the ISO 15189 standard to perform molecular biology analyses (www.cofrac.fr), the biobank of which is S96-900 certified by AFNOR [25]. The second NPS was transported within 4 hours in 400 µl of medium (DA0940.…”

Section: Methodsmentioning

confidence: 99%

“…After homogenization by pipetting from top to bottom of the eluate of the nasal and oral sponges soaked in saline (using D. Dutscher pipettes, reference 134000), they were placed in the Idylla ™ cartridge for SARS-CoV-2 (Biocartis, Belgium, reference A1042/6 and A1043/6) detection, which was performed on a fully automated system for extraction, amplification and detection of nucleic acids using a single-use cartridge (see processing of the sponges in the appendix). After treatment, the residual volume of media was immediately aliquoted and stored at −80°C in the Nice COVID-19 biobank [25]. According to the manufacturer, the Idylla SARS-CoV-2 test provides a qualitative result for the presence or absence of SARS-CoV-2 RNA with a corresponding quality status.…”

Section: Methodsmentioning

confidence: 99%

“…perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Based on our clinical experience on the management of COVID-19 patients and our research on the respiratory epithelium and on COVID-19 [23][24][25][26][27] we aimed to evaluate non-invasive alternatives to NPS for RT-PCR for the diagnosis of COVID-19.…”

Section: Tests With Saliva Involve Amplification Of Viral Rna By Rt-pcr or By Reverse Transcriptasementioning

confidence: 99%

“…Saliva spit in a dry and sterile bottle is preferred; otherwise, saliva is collected using a dedicated system. Based on our research on the respiratory epithelium and on COVID-19 [29][30][31][32][33] we aimed to investigate the potential use of the RT-PCR detection of SARS-COV-2 on oral sponge samples (OS) as an alternative to NP for symptomatic subjects and close contacts.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Salivary detection of COVID-19. Clinical performance of oral sponge sampling for SARS-CoV-2 testing

Marquette

Boutros

Benzaquen

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: The current standard for coronavirus 2019 disease (COVID-19) diagnosis is reverse transcriptase-polymerase chain reaction (RT-PCR) testing of naso-pharyngeal swabs (NPS), Sampling with NPS is invasive and requires specialized and trained personnel, which limits rapid and repeated screening for the disease. A less invasive and possibly self-administered sampling method may increase the capacity for testing and be more effective in identifying, isolating, and filtering out currently infected persons. Methods: Over a period of three months, we included volunteers presenting with recent symptoms suggestive of a SARS-CoV-2 infection at a free COVID-19 screening center in the city of Nice, France. NPS as well as nasal and oral sponges were collected in parallel and analyzed by RT-PCR for SARS-CoV-2. Results: One hundred and forty-seven subjects were included, of whom, 41.5% were diag-nosed with COVID-19 using NPS RT-PCR. RT-PCR on nasal and oral sponges showed a sensitivity of 87 to 98% and 72 to 87%, respectively for diagnosis of COVID-19 in symptomat-ic subjects, depending on the type of RT-PCR technique used. The specificity was 100% whatever the RT-PCR test. The viral load determined with the oral samples was significantly lower than with NPS. Conclusion: Taken together, these results demonstrated that the oral sponge sampling method can be standardized, is easy to use and cheap. The acceptability makes it a repeata-ble test, notably for elderly people or children. It may become a high-frequency - low analyti-cal sensitive testing strategy.

show abstract

A Single Dose of BNT162b2 Messenger RNA Vaccine Induces Airway Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Naive and Recovered Coronavirus Disease 2019 Subjects

Martinuzzi

Benzaquen

Guérin

et al. 2022

Clinical Infectious Diseases

View full text Add to dashboard Cite

Background Mucosal antibodies can prevent virus entry and replication in mucosal epithelial cells and hence virus shedding. Parenteral booster injection of a vaccine against a mucosal pathogen promotes stronger mucosal immune responses following prior mucosal infection compared to injections of a parenteral vaccine in a mucosally naive subject. We investigated whether this was also the case for the BNT162b2 COVID-19 mRNA vaccine. Methods Twenty recovered COVID-19 subjects (RCS) and 23 SARS-CoV-2 naive subjects were vaccinated with respectively one and two doses of the BNT162b2 COVID-19 vaccine. Nasal Epithelial Lining Fluid (NELF) and plasma were collected before and after vaccination and assessed for Immunoglobulin (Ig)G and IgA antibody levels to Spike and for their ability to neutralize binding of Spike to ACE-2 receptor. Blood was analyzed one week after vaccination for the number of Spike-specific Antibody Secreting Cells (ASCs) with a mucosal tropism. Results All RCS had both nasal and blood SARS-CoV-2 specific antibodies at least 90 days after initial diagnosis. In RCS, a single dose of vaccine amplified pre-existing Spike-specific IgG and IgA antibody responses in both NELF and blood against both vaccine homologous and variant strains, including delta. These responses were associated with Spike-specific IgG and IgA ASCs with a mucosal tropism in blood. Nasal IgA and IgG antibody responses were lower in magnitude in SARS-CoV-2 naive subjects after two vaccine doses compared to RCS after one dose. Conclusion Mucosal immune response to the SARS-CoV-2 Spike protein is higher in RCS after a single vaccine dose compared to SARS-CoV-2 naive subjects after two doses.

show abstract

Establishment of a Collection of Blood-Derived Products from COVID-19 Patients for Translational Research: Experience of the LPCE Biobank (Nice, France)

Cited by 12 publications

References 44 publications

Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future

Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future

Salivary detection of COVID-19. Clinical performance of oral sponge sampling for SARS-CoV-2 testing

A Single Dose of BNT162b2 Messenger RNA Vaccine Induces Airway Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Naive and Recovered Coronavirus Disease 2019 Subjects

Contact Info

Product

Resources

About